Aerie Pharmaceuticals Inc
AERIDelisted Nov 21, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001337553
Aerie Pharmaceuticals Inc was delisted on Nov 21, 2022; its insiders filed their last Form 4 on Nov 21, 2022; 156 institutions reported holding it in 13F filings for Q3 2022, worth $710.6M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 156
- Q3 2022, +19 vs. previous quarter
- 13F value
- $710.6M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 0
- At the end of Q3 2022
Superinvestors holding AERI, Q3 2022
No superinvestor reported holding AERI at the end of Q3 2022.
Latest insider trades
Open-market purchases and sales by Aerie Pharmaceuticals Inc insiders from Form 4, newest first.
No open-market purchases or sales by Aerie Pharmaceuticals Inc insiders are on file.
Top 10 13F holders, Q3 2022
The largest institutional positions in Aerie Pharmaceuticals Inc at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 4,855,005 | $73.5M | 1.47% | +159,985+3.4% | Added |
| BlackRock Inc. | 3,544,947 | $53.6M | 0.00% | +113,177+3.3% | Added |
| Vanguard Group Inc | 2,441,120 | $36.9M | 0.00% | −278,367−10.2% | Reduced |
| UBS Group AG | 2,405,832 | $36.4M | 0.02% | +695,195+40.6% | Added |
| Jefferies Group LLC | 2,361,000 | $35.7M | 1.04% | 00.0% | Unchanged |
| Water Island Capital LLC | 2,082,516 | $31.5M | 1.78% | +2,082,516 | New |
| Highland Capital Management Fund Advisors, L.P. | 1,893,891 | $28.7M | 1.92% | +1,584,113+511.4% | Added |
| Rice Hall James & Associates, LLC | 1,603,458 | $24.3M | 1.41% | −241,169−13.1% | Reduced |
| Schroder Investment Management Group | 1,500,183 | $22.7M | 0.04% | −594,628−28.4% | Reduced |
| Morgan Stanley | 1,319,893 | $20.0M | 0.00% | −671,191−33.7% | Reduced |